TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 608-613

  Castillejo, Adela ^a   Rothman, Nathaniel ^b   Murta Nascimento, Cristiane ^c,d   Malats, Núria ^c,d,e   García Closas, Montserrat ^b   Gómez Martínez, Angeles ^a   Lloreta, Josep ^c,f   Tardón, Adonina ^g,h   Serra, Consol ^f,i   García Closas, Reina ^j   Chanock, Stephen ^b   Silverman, Debra T ^b   Dosemeci, Mustafa ^b   Kogevinas, Manolis ^c,d,h,k   Carrato, Alfredo ^a   Soto, José Luis ^a   Real, Francisco X ^c,e,f  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g UNIVERSITY OF OVIEDO   (Spain)

^h CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁱ Department of Pediatrics   (Spain)

^j HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^k UNIVERSITY OF CRETE   (Greece)

more..

Author keywords

Genetic susceptibility; Prognosis; Progression; Recurrence; Survival; Transforming growth factor ; Transforming growth factor receptor; Urinary bladder cancer

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BLADDER TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; URINARY BLADDER NEOPLASMS;

EID: 58149286573     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24013     Document Type: Article

References (24)

1. Jakowlew SB. Transforming growth factor-β in cancer metastasis. Cancer Metastasis Rev 2006;25:435-57.
2. Bierie B, Moses HL. Tumour microenvironment: TGF β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
3. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signalling pathways in human cancer. Cytokine Growth Factors Rev 2006;17:41-58.
4. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.
5. Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C, Accardo A, Verna R, et al. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci 2006;1089:98-103.
6. Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, Cha SI, Kim CH, Park RW, Park SH, Kim YL, Kim IS, et al. Polymorphisms in TGF-β 1 gene and the risk of lung cancer. Lung Cancer 2006;52:1-7.
7. Wei YS, Zhu YH, Du B, Yang ZH, Liang WB, Lv ML, Kuang XH, Tai SH, Zhao Y, Zhang L. Association of transforming growth factor-β 1 gene polymorphisms with the genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 2007;380:165-9.
8. Mazur G, Bogunia-Kubik K, Wrobel T, Kuliczkowski K, Lange A. TGF-β1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006;33:145-9.
9. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 2004;22:756-8.
10. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, et al. TGF β R-I (6A) is a candidate tumor susceptibility allele. Cancer Res 1999;59:5678-82.
11. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005;294:1634-46.
12. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and the cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003;21: 3236-43.
13. García-Closas M, Malats N, Silverman D, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager Y, et al. NAT2 slow acetylation. GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. Lancet 2005;366:649-59.
14. Reuter VE, Epstein JI, Amin MB, Mostofi FK. The WHO/IUSP consensus classification of urothelial (transitional cell) neoplasms: continued discussion. Hum Pathol 1999;30:879-80.
15. Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N, Real FX; on behalf of the EPICURO Study Investigators. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-71.
16. García-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D, Kogevinas M, Dosemeci M, Figueroa JD, Chatterjee N, Tardón A, Serra C, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007;3:0287-93.
17. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928-9.
18. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007;23:1038-9.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
20. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β 1 gene: association with transforming growth factor-β 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
21. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P. Transforming growth factor-β 1 hyperexpression in African-American hypertensives: a novel mediator of hipertension and/or target organ damage. Proc Natl Acad Sci USA 2000;97:3479-84.
22. Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE, Gunn J, Jeffery S, Heathcote K. Transforming growth factor β 1 gene polymorphisms and coronary artery disease. Clin Sci 1998;95:659-67.
23. Skoglund J, Song B, Dalen J, Dedorson S, Edler D, Hjern F, Holm J, Lenander C, Lindforss U, Lundqvist N, Olivecrona H, Olsson L, et al. Lack of an association between the TGFBR16A variant and colorectal cancer risk. Clin Cancer Res 2001;13:3148-52.
24. van Tilborg AAG, de Vries A, Zwarthoff EC. The chromosome 9q genes TGFBR1. TSC1 and ZNF189 are rarely mutated in bladder cancer. J Pathol 2001;194:16-80.